AR061303A1 - Proceso para sintetizar compuestos de piperazina-piperidina - Google Patents
Proceso para sintetizar compuestos de piperazina-piperidinaInfo
- Publication number
- AR061303A1 AR061303A1 ARP070102505A ARP070102505A AR061303A1 AR 061303 A1 AR061303 A1 AR 061303A1 AR P070102505 A ARP070102505 A AR P070102505A AR P070102505 A ARP070102505 A AR P070102505A AR 061303 A1 AR061303 A1 AR 061303A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compound
- piperazine
- haloalkyl
- alkynyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- LMRCKXYHPYNEJV-UHFFFAOYSA-N piperazine;piperidine Chemical class C1CCNCC1.C1CNCCN1 LMRCKXYHPYNEJV-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 6
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 2
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 abstract 2
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 abstract 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La presente se refiere a procesos para sintetizar compuestos de piperazina-piperidina y compuestos utiles como agentes de enlace de 5-HT1A, particularmente como antagonistas y agonistas del receptor 5-HT1A. El proceso también permite una produccion ambientalmente tolerante y más segura de estos compuestos utiles. Reivindicacion 1: Un proceso para aislar un compuesto que tiene la formula 1, o una sal farmacéuticamente aceptable del mismo, en donde R1, R2, R3, R4, R5, y R6, son cada uno independientemente -H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, o alquinilo C2-6, halogeno, -CF3, -NO2, -CN, -OR25, -OSOR25, -SR25, -SO2R25, -SO2N(R25)2, -N(R25)2, C(O), -COR25, -CO2R25, -NR25CO2R25, -NR25COR25, -R25CON(R25)2, o -CON(R25)2; Ra y Rb son cada uno independientemente -H o -CH3 y R25 es H; o alquilo C1-6 lineal o ramificado, haloalquilo C1-6, alquenilo C2-6, o alquinilo C2-6, el proceso caracterizado porque comprende: (a) hacer reaccionar un compuesto que tiene la formula 1 con un ácido dicarboxílico para formar una sal de adicion del compuesto que tiene la formula 1; (b) aislar el compuesto de la formula 1 de la sal de adicion de la formula 1 en la presencia de un solvente orgánico, una base, y CH2Cl2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81214806P | 2006-06-09 | 2006-06-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061303A1 true AR061303A1 (es) | 2008-08-20 |
Family
ID=38669840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102505A AR061303A1 (es) | 2006-06-09 | 2007-06-08 | Proceso para sintetizar compuestos de piperazina-piperidina |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080058523A1 (es) |
| EP (1) | EP2035384A2 (es) |
| JP (1) | JP2009539849A (es) |
| CN (1) | CN101466680A (es) |
| AR (1) | AR061303A1 (es) |
| AU (1) | AU2007258552A1 (es) |
| BR (1) | BRPI0712153A2 (es) |
| CA (1) | CA2650934A1 (es) |
| MX (1) | MX2008015050A (es) |
| PE (1) | PE20080934A1 (es) |
| TW (1) | TW200808730A (es) |
| WO (1) | WO2007146072A2 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200800959A (en) | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
| AR063984A1 (es) * | 2006-11-28 | 2009-03-04 | Wyeth Corp | Metabolitos de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina, metodos de preparacion, su uso en la fabricacion de medicamentos para el tratamiento de trastornos relacionados con 5-ht1a, composicion farmaceutica que los comprende, compuestos radioetiquetados derivado |
| CN105037389B (zh) * | 2015-06-09 | 2017-09-05 | 丹诺医药(苏州）有限公司 | 一种利福霉素‑硝基咪唑偶联分子的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60011570T2 (de) * | 1999-01-07 | 2004-11-25 | Wyeth | Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen |
| DE10043659A1 (de) * | 2000-09-05 | 2002-03-14 | Merck Patent Gmbh | Arylpiperazinderivate |
| US7276603B2 (en) * | 2003-05-02 | 2007-10-02 | Wyeth | Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use |
| MY179926A (en) * | 2003-12-08 | 2020-11-19 | Wyeth Corp | Process for the preparation of tubulin inhibitors |
| TW200800959A (en) * | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
-
2007
- 2007-05-31 TW TW096119519A patent/TW200808730A/zh unknown
- 2007-06-07 US US11/811,328 patent/US20080058523A1/en not_active Abandoned
- 2007-06-07 EP EP07795854A patent/EP2035384A2/en not_active Withdrawn
- 2007-06-07 BR BRPI0712153-9A patent/BRPI0712153A2/pt not_active IP Right Cessation
- 2007-06-07 JP JP2009514376A patent/JP2009539849A/ja active Pending
- 2007-06-07 WO PCT/US2007/013433 patent/WO2007146072A2/en not_active Ceased
- 2007-06-07 PE PE2007000705A patent/PE20080934A1/es not_active Application Discontinuation
- 2007-06-07 CA CA002650934A patent/CA2650934A1/en not_active Abandoned
- 2007-06-07 MX MX2008015050A patent/MX2008015050A/es unknown
- 2007-06-07 AU AU2007258552A patent/AU2007258552A1/en not_active Abandoned
- 2007-06-07 CN CNA2007800213858A patent/CN101466680A/zh active Pending
- 2007-06-08 AR ARP070102505A patent/AR061303A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007258552A1 (en) | 2007-12-21 |
| CN101466680A (zh) | 2009-06-24 |
| WO2007146072A2 (en) | 2007-12-21 |
| BRPI0712153A2 (pt) | 2012-01-24 |
| WO2007146072A3 (en) | 2008-05-29 |
| US20080058523A1 (en) | 2008-03-06 |
| CA2650934A1 (en) | 2007-12-21 |
| PE20080934A1 (es) | 2008-09-10 |
| EP2035384A2 (en) | 2009-03-18 |
| TW200808730A (en) | 2008-02-16 |
| JP2009539849A (ja) | 2009-11-19 |
| MX2008015050A (es) | 2008-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR080057A1 (es) | Piridinas disustituidas como anticancerigenos | |
| AR061924A1 (es) | Proceso para elaborar 2- amino -5 - halobenzamidas 3- sustituidas | |
| CO6150158A2 (es) | Piperidinas sustituidas que aumentan la actividad de p53 y su uso | |
| AR116300A1 (es) | Proceso para la preparación de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilato de metilo | |
| PE20141203A1 (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| CO6220910A2 (es) | Proceso para la producir compuestos pesticidas de benzamidas | |
| JP2017511305A5 (es) | ||
| AR069838A1 (es) | Proceso para la preparacion de derivados de acido 2-amino-5-cianobenzoico | |
| PE20130311A1 (es) | Composiciones y metodos para modular la via de senalizacion de wnt | |
| AR075084A1 (es) | Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes | |
| AR047744A1 (es) | Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotropico | |
| AR047533A1 (es) | Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la quinasa | |
| PE20120937A1 (es) | Compuestos derivados de quinolina y quinoxalina como agentes antivirales | |
| PE20142282A1 (es) | Nuevos derivados de aril-quinolina | |
| PE20081164A1 (es) | Nuevos compuestos 521 | |
| PE20070419A1 (es) | Derivados de benzoquinazolina | |
| AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
| AR079495A1 (es) | Derivados de fenilimidazol heteroaromaticos como inhibidores de enzima pde10a | |
| PE20130246A1 (es) | COMPUESTOS DEL COMPLEJO DE Fe(III) PARA EL TRATAMIENTO Y PROFILAXIS DE LOS SINTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO | |
| BR112014004144B1 (pt) | composição de ionômero antimicrobiana compreendendo um composto de polímero catiônico de funcionalidade amina e halogeneto de prata, método de produção da composição e usos da mesma | |
| AR061303A1 (es) | Proceso para sintetizar compuestos de piperazina-piperidina | |
| JP2018502174A5 (es) | ||
| BRPI0808570B8 (pt) | processo para a preparação de inibidores de glyt-1 | |
| AR057909A1 (es) | Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico. | |
| PE20061362A1 (es) | Derivados de tetrahidronaftalina, procedimientos para su preparacion y su uso como inhibidor de la inflamacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |